ClinicaliQ Trial Snapshot
- Fibrosis Associated Protein Inhibitor (FAPI) Radiotracer-based Imaging to Identify Fibrotic Intestinal Crohn’s Disease — Recruiting • Cardiology / Cardiovascular • NCT07152431.
- What is being tested: Fibrosis-associated protein inhibitor (FAPI) radiotracer imaging as a novel diagnostic tool to identify and characterise fibrotic strictures in Crohn's Disease patients, potentially enabling earlier detection of intestinal fibrosis before symptomatic complications develop.
- Patient eligibility overview: The trial targets adult Crohn's Disease patients with known or suspected fibrotic stricturing disease, including those with obstructive symptoms or previous imaging findings suggestive of intestinal fibrosis.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Crohn's Disease (CD) is a chronic inflammatory condition that can affect any part of the intestine and currently has no cure. It affects 6.8 million people worldwide with UK healthcare costs in excess of £1 billion per year. Recent data suggests that the despite significant progress in treatments over the last 2 decades to help control disease, up to half of patients still develop progressive bowel scarring that require surgery and up to 70% needing surgery within 10-20 years from diagnosis. Unfortunately this is not a cure and some still…
Eligibility Snapshot
- : * Crohn's disease with ileal involvement (including those with disease recurrence in the neo-terminal ileum) due to commence biologics.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.